Literature DB >> 12747884

Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder.

Jürgen Groet1, Suzanne McElwaine, Monica Spinelli, Andrea Rinaldi, Ingo Burtscher, Claire Mulligan, Afua Mensah, Simona Cavani, Franca Dagna-Bricarelli, Giuseppe Basso, Finbarr E Cotter, Dean Nizetic.   

Abstract

Transient myeloid disorder is a unique self-regressing neoplasia specific to Down's syndrome. The transcription factor GATA1 is needed for normal growth and maturation of erythroid cells and megakaryocytes. Mutations in GATA1 have been reported in acute megakaryoblastic leukaemia in Down's syndrome. We aimed to investigate changes in GATA1 in patients with Down's syndrome and either transient myeloid disorder (n=10) or acute megakaryoblastic leukaemia (n=6). We recorded mutations eliminating exon 2 from GATA1 in all patients with transient myeloid disorder (age 0-24 days) and in all with acute megakaryoblastic leukaemia (age 14-38 months). The range of mutations did not differ between patients with each disorder. Patients with transient myeloid disorder with mutations in GATA1 can regress spontaneously to complete remission, and mutations do not necessarily predict later acute megakaryoblastic leukaemia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12747884     DOI: 10.1016/S0140-6736(03)13266-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  32 in total

Review 1.  GATA transcription factors in hematologic disease.

Authors:  Alan B Cantor
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

2.  GATA1 mutations in a cohort of Malaysian children with Down syndrome-associated myeloid disorder.

Authors:  Su Han Lum; Soo Sin Choong; Shekhar Krishnan; Zulqarnain Mohamed; Hany Ariffin
Journal:  Singapore Med J       Date:  2016-06       Impact factor: 1.858

Review 3.  Evolution of myeloid leukemia in children with Down syndrome.

Authors:  Satoshi Saida
Journal:  Int J Hematol       Date:  2016-02-24       Impact factor: 2.490

4.  Tumorigenesis in Down's syndrome: big lessons from a small chromosome.

Authors:  Dean Nižetić; Jürgen Groet
Journal:  Nat Rev Cancer       Date:  2012-09-21       Impact factor: 60.716

5.  Distinct clones are associated with the development of transient myeloproliferative disorder and acute megakaryocytic leukemia in a patient with Down syndrome.

Authors:  Hirokazu Kanegane; Sayaka Watanabe; Keiko Nomura; Gang Xu; Etsuro Ito; Toshio Miyawaki
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

6.  Cooperation between the GATA and RUNX factors Serpent and Lozenge during Drosophila hematopoiesis.

Authors:  Lucas Waltzer; Géraldine Ferjoux; Laetitia Bataillé; Marc Haenlin
Journal:  EMBO J       Date:  2003-12-15       Impact factor: 11.598

Review 7.  Haematology of Down syndrome.

Authors:  David Webb; Irene Roberts; Paresh Vyas
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-09-05       Impact factor: 5.747

8.  Developmental differences in IFN signaling affect GATA1s-induced megakaryocyte hyperproliferation.

Authors:  Andrew J Woo; Karen Wieland; Hui Huang; Thomas E Akie; Taylor Piers; Jonghwan Kim; Alan B Cantor
Journal:  J Clin Invest       Date:  2013-07-01       Impact factor: 14.808

9.  The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy.

Authors:  Y Ge; K M LaFiura; A A Dombkowski; Q Chen; S G Payton; S A Buck; S Salagrama; A E Diakiw; L H Matherly; J W Taub
Journal:  Leukemia       Date:  2007-12-20       Impact factor: 11.528

10.  Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome.

Authors:  Diane C Cabelof; Hiral V Patel; Qing Chen; Holly van Remmen; Larry H Matherly; Yubin Ge; Jeffrey W Taub
Journal:  Blood       Date:  2009-07-24       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.